How Novartis' cancer drug Tasigna restores critical dopamine that's lost to Parkinson's disease

Georgetown University researchers have been studying Novartis’ cancer drug Tasigna as a potential treatment for Parkinson’s disease since 2013. Now, they're out with new research from a phase 2 trial showing that the drug boosts dopamine levels in the brain while also reducing levels of neurotoxic proteins, halting the decline of both motor and non-motor functioning.